Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Clin Cancer Res. 2008 Dec 1;14(23):7711–7716. doi: 10.1158/1078-0432.CCR-08-1364

Fig. 3.

Fig. 3

Requirement for lymphocytes and iDCs. A, combining G47Δ infection of subcutaneous N18 tumors with intratumoral iDC injection does not slow progression relative to treatment with G47Δ alone in immunodeficient NOD-SCID mice. B, combining G47Δ injection of subcutaneous N18 tumors with intratumoral injection of mature dendritic cells does not slow progression relative to treatment with G47Δ alone in syngeneic A/J mice (G47Δ/mature dendritic cells versus G47Δ, P = 0.8; G47Δ versus G47Δ/iDC, P = 0.02; G47Δ/iDC versus G47Δ/mature dendritic cells, P = 0.15, Student’s t test). Enhanced antitumor effect is dependent on use of iDCs.